Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

Synergic Effect of Mahwangyounpae-tang and Ciprofloxacin on 5 Strains of Aerobic Gram-negative Bacteria

마황윤폐탕(麻黃潤肺湯)과 Ciprofloxacin의 병용(倂用)이 호기성 Gram(-) 세균주(細菌株)에 대한 시험관내(試驗管內) 항균력(抗菌力)에 미치는 영향

  • Liu, Han-Hsiang (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University) ;
  • Park, Mee-Yeon (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University) ;
  • Choi, Hae-Yun (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University) ;
  • Gu, Deok-Mo (Division of Sasang Constitutionnal Mecicine, College of Oriental Medicine, Daegu Haany University) ;
  • Kim, Jong-Dae (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University) ;
  • Song, Kwang-Kyu (Division of Respiratory System, College of Oriental Medicine, Daegu Haany University)
  • 유한상 (대구한의대 한의학과 폐계내과학교실) ;
  • 박미연 (대구한의대 한의학과 폐계내과학교실) ;
  • 최해윤 (대구한의대 한의학과 폐계내과학교실) ;
  • 구덕모 (대구한의대 한의학과 사상의학교실) ;
  • 김종대 (대구한의대 한의학과 폐계내과학교실) ;
  • 송광규 (대구한의대 한의학과 폐계내과학교실)
  • Published : 2005.06.25
Download PDF
⟨ Previous Next ⟩

Abstract

In order to evaluate the in vitro synergic effect of Mahwangyounpae-tang which was a traditional poly-herbal formula has been used in the treatment of respiratory diseases in oriental medicine, and quinolone antibiotics, ciprofloxacin (CPFX), the minimal inhibitory concentration (MIC), $MIC_{50}$ and MIC90 of single use of quinolones and concomitant treatment with Mahwangyounpae-tang against 5 strains of aerobic gram negative bacteria, Escherichia coli, Klebsiella peumoniae, Hemophilus influenzae, Citrobacter freundii and Pseudomonas aeruginosae. The obtained results were as follows : In the case of aerobic gram negative bacteria, the MIC, $MIC_{50}$ and $MIC_{90}$ against Klebsiella peumoniae and Pseudomonas aeruginosae was significantly decreased in concomitant treated groups with Mahwangyounpae-tang compared to those of single treated groups of CPFX, respectively. However, no significant changes were demonstrated against Echerichia coli, Hemophilus influenzae and Citrobacter freundii. According to these results, it is considered as the in vitro antibacterial activity of CPFX was dramatically increased by concomitant use of Mahwangyounpae-tang against some strains of aerobic gram negative bacteria and the increase and selectivity of antibacterial activities against strains were chosen by the selectivity of Mahwangyounpae-tang not CPFX activity.

Keywords

References

  1. Maritnez, E., Marcos, A. Antibiotic- associated diarrhea. Lancet 337, 91, 1991.
  2. 대구한의대학교부속한방병원. 원내처방집. P 53, 88문화사, 대구, 1998.
  3. 감철우. 麻黃潤肺陽이 ovalbumin으로 誘發된 mouse의 喘息에 미치는 影響. 대구한의대학교 대학원 박사학위논문 2001.
  4. 박미연, 김대준, 김종대. 麻黃潤肺湯의 병용이 Quinolone계 항생제중 Rufloxacin 의 호기성 Gram(+)세 균주에 대한 시험 관내 향균력에 미치는 영향. 대한본초학회지 18(4):65-72, 2003.
  5. 김대준, 김종대. 麻黃潤師傷과 Ciprofloxacin 병용이 Gram(+) 중 혐기성 균주 7종에 대한 시험관내 향균력에 미치는 영향. 대한본초학회지, 18(3):161-168, 2003.
  6. 崔達永, 傷寒論釋講. p 74-78, 대성문화사, 서울, 1995.
  7. 李尙仁. 方劑學. P 40,310,332, 永林社, 서울, 1996.
  8. Appelbaum, P.C., Hunter, P.A. The fluoroquinolone antibacterials: past, present and future perspectives. lnt J Antimicrob Agents 16, 5-15, 2000.
  9. Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 46, 17-24, 2000.
  10. Farker, K., Naber, K.G., Funfstuck, R. Fluoroquinolones: utilization in renal and urogenital tract infections. Med Klin 96, 383-390, 2001.
  11. Paladino, J.A. Is more than one quinolone needed in clinical practice? Ann Pharmacother 35, 1085-1095, 2001.
  12. Wiseman, L.R., Balfour, J.A. Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging 4, 145-173, 1994.
  13. Fass, R.J. Ciprofloxacin. Best use of this new broadspectrum antibiotic. Postgrad. Med. 87, 117-122, 1990.
  14. Hoppe, J.E., Rahimi-Calougahi, E., Seibert, G. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (leveofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome and meropenem. Antimocrob Agents Chemother 40,807-808,1996.
  15. Wise, R., Andrews, J.M. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens. J Chemother 10, 276-279, 1998.
  16. Ermertcan. S., Hosgor, M., Tunger, O., Cosar, G. Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosae and Acinetobacter strains isolated from intensive care unit infections. Scand J Infect Dis 33, 818-821, 2001.
  17. Joyanes. P., Pascual, A., Gimenez, M.J., Garcia, I., Aguilar, L., Perea, E. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae. Chemotheraphy 47, 409-414, 2001.
  18. Pispirigos, K., Chrysanthopoulos, K. Evaluation of cardiac subacutetoxicity of ciprofloxacin in rats using serum biochemical parameters. Arzneimittelforschung 51, 582-587, 2001.
  19. Pons, R., Escutia, B. Ciprofloxacin-induced vasculitis with cutaneous and renal involvement. Nefrologia 21, 209-212, 2001.
  20. Egerbacher, M., Edinger, J., Tschulenk, W. Effects of emofloxacin and ciprofloxacin hydrochloride on canine and equine chondrocytes in culture. Am J Vet Res 62, 704-708, 2001.
  21. Williams, R.J. III, Attia, K, Wickiewicz, T.L., Hannafin, J.A. The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med 28, 364-369, 2000.
  22. Cunha, B.A. Antibiotic resistance. Med Clin North Am 84, 1407-1429, 2000.